表紙
市場調查報告書
商品編碼
1070415

血漿分餾製劑市場 (免疫球蛋白、血友病、特殊製劑、白蛋白):分析、預測、COVID-19的潛在影響 (2022-2026年)

Plasma Derived Therapies Market (Immunoglobulin, Hemophilia, Specialty, and Albumin): Insights & Forecast with Potential Impact of COVID-19 (2022-2026)

出版日期: | 出版商: Koncept Analytics | 英文 106 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球血漿分餾製劑的市場規模,在預測期間內預計以7.20%的年複合成長率發展,2026年成長到507億美元的規模。

老年人口增加,遺傳性疾病的盛行率增加,政府的配合措施,白蛋白的需求增加,醫藥品的血漿蛋白質的使用的劇增,免疫球蛋白的使用增加,自體免疫疾病的劇增等要素促進該市場的成長。同時,市場預計面臨高成本和嚴格法規等課題。

本報告提供全球血漿分餾製劑的市場調查,市場概要,市場成長的各種影響因素分析,市場規模的變化、預測,各種區分、各地區/主要國家的明細,主要企業簡介等彙整資訊。

目錄

第1章 市場概要

  • 血漿分餾製劑
  • 血漿分餾製劑的分類
    • 免疫球蛋白
    • 血友病
    • 白蛋白
  • 血漿分餾製劑的製造流程
  • 血漿分餾製劑的價值鏈
  • 對患者的血漿分餾製劑的優點

第2章 COVID-19影響

第3章 全球市場的分析

  • 市場規模
  • 市場規模的預測
  • 市場規模、預測:各類型
    • 免疫球蛋白血漿分餾製劑
    • 血友病血漿分餾製劑
    • 特殊血漿分餾製劑
    • 白蛋白血漿分餾製劑
  • 市場規模:各地區

第4章 市場分析:各地區

  • 北美
  • 歐洲
  • 亞太地區
  • 南美

第5章 市場動態

  • 成長要素
  • 主要趨勢、展開
  • 課題

第6章 競爭情形

  • 全球市場
  • 美國及歐洲市場
  • 美國市場

第7章 企業簡介

  • CSL Limited
  • Grifols
  • Takeda Pharmaceutical Company
  • Octapharma AG
  • Kedrion
  • ADMA Biologics
目錄

The global plasma derived therapy market is anticipated to reach US$50.70 billion in 2026, growing at a CAGR of 7.20% during the period spanning 2022-2026. The growth in the market has been driven by factors like rising geriatric population, increasing prevalence of genetic disorders, government initiatives, rising demand for albumin, escalating use of plasma proteins in pharmaceuticals, increasing usage of immunoglobulin, surging autoimmune disorders. The market is expected to face certain challenges such as high cost and stringent regulations. To overcome these challenges, the market would witness some key trends like technological advancements, rising demand for health insurance, escalating use of therapeutic protein drugs, and increasing adoption of plasma therapy in neurology.

The global plasma derived therapy market can be segmented as follows: Immunoglobulin, Hemophilia, Specialty, and Albumin. Immunoglobulin held a larger share of the market in 2021. Due to the rising use in primary immunodeficiency and neurological applications, the immunoglobulins market is predicted to grow. For example, Grifols, S.A., a pharmaceutical and chemical company, launched HyperHEP B, a new formulation of immune globulin derived from human plasma for hepatitis B postexposure prophylaxis, in June 2021, propelling the industry forward.

The global plasma derived therapy market by region can be segmented into the following: North America, Europe, Asia Pacific, and LAMEA. North America held a larger share of the market in 2021. Growing use of immunoglobulins in various therapeutic domains, increased plasma collection (and the number of plasma collection facilities), and rising prevalence of respiratory disorders and alpha-1-antitrypsin deficiency are all driving market expansion (AATD).

Scope of the report:

  • The report provides a comprehensive analysis of the global plasma derived therapy market, segmented into Immunoglobulin, Hemophilia, Specialty, and Albumin.
  • The major regional markets North America, Europe, Asia Pacific, and LAMEA have been analyzed.
  • The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.
  • The competitive landscape of the market, along with the company profiles of leading players (ADMA Biologics, Kedrion, Grifols, Takeda Pharmaceutical Company, Octapharma, and CSL Limited) are also presented in detail.

Key Target Audience:

  • Plasma collection Centers
  • End Users (Hospital, Medical centers, Clinical Institutes)
  • Healthcare Consulting Firms
  • Investment Banks
  • Government Bodies & Regulating Authorities

Table of Contents

1. Market Overview

  • 1.1 Plasma-Derived Therapies
    • 1.1.1 Introduction
  • 1.2 Segments of Plasma Derived Therapies
    • 1.2.1 Immunoglobulin
    • 1.2.2 Hemophilia
    • 1.2.3 Albumin
  • 1.3 Plasma Derived Therapy Production Process
  • 1.4 Value Chain of Plasma Derived Therapy
  • 1.5 Advantages of Plasma Derived Therapy for Patients

2. Impact of COVID-19

  • 2.1 Impact of COVID-19 on HealthCare Market
  • 2.2 Impact of COVID-19 on Plasma
  • 2.3 Impact of COVID-19 on Plasma Collection
  • 2.4 Prevalence of COVID-19

3. Global Market Analysis

  • 3.1 Global Plasma Derived Therapy Market by Value
  • 3.2 Global Plasma Derived Therapy Market Forecast by Value
  • 3.3 Global Plasma Derived Therapy Market by Segments
    • 3.3.1 Global Immunoglobulin Plasma Derived Therapy Market by Value
    • 3.3.2 Global Immunoglobulin Plasma Derived Therapy Market Forecast by Value
    • 3.3.3 Global Immunoglobulin Plasma Derived Therapy Market by Segments
    • 3.3.4 Global Immunoglobulin Plasma Derived Therapy Market Forecast by Segments
    • 3.3.5 Global Hemophilia Plasma Derived Therapy Market by Value
    • 3.3.6 Global Hemophilia Plasma Derived Therapy Market Forecast by Value
    • 3.3.7 Global Hemophilia Plasma Derived Therapy Market Forecast by Segments
    • 3.3.8 Global Hemophilia Plasma Derived Therapy Market Forecast by Segments
    • 3.3.9 Global Specialty Plasma Derived Therapy Market by Value
    • 3.3.10 Global Specialty Plasma Derived Therapy Market Forecast by Value
    • 3.3.11 Global Albumin Plasma Derived Therapy Market by Value
    • 3.3.12 Global Albumin Plasma Derived Therapy Market Forecast by Value
  • 3.4 Global Plasma Derived Therapy Market by Region

4. Regional Market Analysis

  • 4.1 North America
    • 4.1.1 North America Plasma Derived Therapy Market Forecast by Value
    • 4.1.2 North America Plasma Derived Therapy Market by Region
    • 4.1.3 The US Plasma Derived Therapy Market Forecast by Value
  • 4.2 Europe
    • 4.2.1 Europe Plasma Derived Therapy Market Forecast by Value
  • 4.3 Asia Pacific
    • 4.3.1 Asia Pacific Plasma Derived Therapy Market Forecast by Value
  • 4.4 LAMEA
    • 4.4.1 LAMEA Plasma Derived Therapy Market Forecast by Value

5. Market Dynamics

  • 5.1 Growth Drivers
    • 5.1.1 Rising Geriatric Population
    • 5.1.2 Increasing Prevalence of Genetic Disorders
    • 5.1.3 Government Initiatives
    • 5.1.4 Rising Demand for Albumin
    • 5.1.5 Escalating Use of Plasma Proteins in Pharmaceuticals
    • 5.1.6 Increasing Usage of Immunoglobulin
    • 5.1.7 Suring Autoimmune Disorders
  • 5.2 Key Trends and Developments
    • 5.2.1 Technological Advancements
    • 5.2.2 Rising Demand for Health Insurance
    • 5.2.3 Escalating Use of Therapeutic Protein Drugs
    • 5.2.4 Increasing Adoption of Plasma Therapy in Neurology
  • 5.3 Challenges
    • 5.3.1 High Cost
    • 5.3.2 Stringent Regulations

6. Competitive Landscape

  • 6.1 Global Market
    • 6.1.1 Revenues Comparison- Key Players
    • 6.1.2 Market Capitalization Comparison- Key Players
    • 6.1.3 Research & Development Expenses Comparison - Key Players
    • 6.1.4 Selected Drugs Approved or In Development for AATD- Key Players
    • 6.1.5 Plasma Market Share- Key Players
    • 6.1.6 Immunoglobulin Market Share- Key Players
    • 6.1.7 Albumin Market Share- Key Players
  • 6.2 The US and Europe Market
    • 6.2.1 The US and EU Collection Centers Key Players
  • 6.3 The US Market
    • 6.3.1 Acquisitions of U.S.-based Plasma Centers - Key Players

7. Company Profiles

  • 7.1 CSL Limited
    • 7.1.1 Business Overview
    • 7.1.2 Financial Overview
    • 7.1.3 Business Strategies
  • 7.2 Grifols
    • 7.2.1 Business Overview
    • 7.2.2 Financial Overview
    • 7.2.3 Business Strategies
  • 7.3 Takeda Pharmaceutical Company
    • 7.3.1 Business Overview
    • 7.3.2 Financial Overview
    • 7.3.3 Business Strategies
  • 7.4 Octapharma AG
    • 7.4.1 Business Overview
    • 7.4.2 Financial Overview
    • 7.4.3 Business Strategies
  • 7.5 Kedrion
    • 7.5.1 Business Overview
    • 7.5.2 Financial Overview
    • 7.5.3 Business Strategies
  • 7.6 ADMA Biologics
    • 7.6.1 Business Overview
    • 7.6.2 Financial Overview
    • 7.6.3 Business Strategies

List of Figures

  • Segments of Plasma Derived Therapies
  • Plasma Derived Therapy Production Process
  • Value Chain of Plasma Derived Therapy
  • Advantages of Plasma Derived Therapy for Patients
  • Volume of Plasma Collected in the US and Number of US-based Collection Centres (2016- 2020)
  • Rising Coronavirus Cases in the US (Feb 2020- Mar 2022)
  • Global Plasma Derived Therapy Market by Value (2017-2021)
  • Global Plasma Derived Therapy Market Forecast by Value (2022-2026)
  • Global Plasma Derived Therapy Market by Segments (2021)
  • Global Immunoglobulin Plasma Derived Therapy Market by Value (2017-2021)
  • Global Immunoglobulin Plasma Derived Therapy Market Forecast by Value (2022-2026)
  • Global Immunoglobulin Plasma Derived Therapy Market by Segments (2021)
  • Global Immunoglobulin Plasma Derived Therapy Market Forecast by Segments (2021-2026)
  • Global Hemophilia Plasma Derived Therapy Market by Value (2017-2021)
  • Global Hemophilia Plasma Derived Therapy Market Forecast by Value (2022-2026)
  • Global Hemophilia Plasma Derived Therapy Market by Segments (2021)
  • Global Hemophilia Plasma Derived Therapy Market Forecast by Segments (2021-2026)
  • Global Specialty Plasma Derived Therapy Market by Value (2017-2021)
  • Global Specialty Plasma Derived Therapy Market Forecast by Value (2022-2026)
  • Global Albumin Plasma Derived Therapy Market by Value (2017-2021)
  • Global Albumin Plasma Derived Therapy Market Forecast by Value (2022-2026)
  • Global Plasma Derived Therapy Market by Region (2021)
  • North America Plasma Derived Therapy Market Forecast by Value (2020-2026)
  • North America Plasma Derived Therapy Market by Region (2021)
  • The US Plasma Derived Therapy Market Forecast by Value (2020-2026)
  • Europe Plasma Derived Therapy Market Forecast by Value (2020-2026)
  • Asia Pacific Plasma Derived Therapy Market Forecast by Value (2020-2026)
  • LAMEA Plasma Derived Therapy Market Forecast by Value (2020-2026)
  • Global Geriatric Population (2016-2020)
  • Diagnosed Prevalence Cases of Rheumatoid Arthritis in Eight Major Markets (2019-2029)
  • The U.S. Health and Medical Insurance (2018-2022)
  • Key Players - Plasma Market Share (2021)
  • Key Players - Immunoglobulin Market Share (2021)
  • Key Players - Albumin Market Share (2021)
  • Key Players -The US and EU collection Centers (2021)
  • CSL Limited Operating Revenue and Net Profit (2017-2021)
  • CSL Limited Operating Revenue by Segment (2021)
  • CSL Limited Operating Revenue by Region (2021)
  • Grifols Net Revenues and Group Profit (2017-2021)
  • Grifols Net Revenue by Segments (2021)
  • Grifols Net Revenues by Regions (2021)
  • Takeda Pharmaceutical Company Revenue and Net Profit (2017-2021)
  • Takeda Pharmaceutical Company Revenue by Therapeutic Area (2021)
  • Takeda Pharmaceutical Company Revenue by Region (2021)
  • Octapharma Revenues and Net Profit of the Year (2017-2021)
  • Kedrion Revenues from Sales & Services and Net Result for the Period (2016-2020)
  • Kedrion Revenues from Sales & Services by Regions (2021)
  • ADMA Revenues and Net Loss (2017-2021)
  • ADMA Revenues by Segment (2021)
  • ADMA Revenues by Region (2021)

List of Tables

  • Key Players - Revenues Comparison (2020/2021)
  • Key Players - Market Capitalization Comparison (2021)
  • Key Players - Research & Development Expenses Comparison (2020/2021)
  • Key Players - Selected Drugs Approved or In Development for AATD
  • Key Players - Acquisitions of U.S.-based Plasma Centers